CliffBio
biologic

Susvimo

ranibizumab

Loss of exclusivityOctober 2033projected — 12-year biologic exclusivity estimate
CompanyGenentech →See this company's full patent-cliff portfolio

Drug detail

Brand nameSusvimo
Active ingredientranibizumab
Strength100MG/ML
Dosage formInjection
RouteIntravitreal
ModalityBiologic
FDA approvalOctober 2021
Marketing statusRx

More from Genentech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Susvimo patent cliff — loss of exclusivity October 2033 | CliffBio